Does cancer clinical trial enrollment for sexual and gender minority people differ from heterosexual, cisgender people?

IF 2 3区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Contemporary clinical trials Pub Date : 2024-09-18 DOI:10.1016/j.cct.2024.107695

Ash B. Alpert , Juno Obedin-Maliver , Annie Gjelsvik , Siraj Amanullah , Theresa I. Shireman , John R. Blosnich

{"title":"Does cancer clinical trial enrollment for sexual and gender minority people differ from heterosexual, cisgender people?","authors":"Ash B. Alpert , Juno Obedin-Maliver , Annie Gjelsvik , Siraj Amanullah , Theresa I. Shireman , John R. Blosnich","doi":"10.1016/j.cct.2024.107695","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Sexual and gender minority (SGM) people experience cancer disparities compared to heterosexual and cisgender (non-SGM) people and likely have barriers to cancer clinical trial enrollment. Data are sparse, however, regarding cancer clinical trial enrollment for SGM versus non-SGM people.</div></div><div><h3>Methods</h3><div>Using data from the 2020 Behavioral Risk Factor Surveillance Survey (BRFSS), we applied a logistic regression to assess associations between SGM status and clinical trial enrollment for 346 SGM and 9441 non-SGM people diagnosed with cancer. The model was adjusted for age at diagnosis, race/ethnicity, partnership status, education, employment, and sex assigned at birth.</div></div><div><h3>Results</h3><div>SGM individuals had 94 % greater odds than non-SGM individuals to report participation in a clinical trial (aOR 1.94; 95 % CI 1.02–3.68) after adjusting for other factors.</div></div><div><h3>Conclusions</h3><div>Data from the BRFSS suggest that SGM people with cancer have higher odds of clinical trial enrollment compared to non-SGM people with cancer. Future work is needed to prospectively track oncology treatment, including clinical trial participation, and outcomes of SGM people versus non-SGM people with cancer. Other studies will be needed to develop and implement systematic, consistent, and non-stigmatizing sexual orientation and gender identity data collection methods.</div></div>","PeriodicalId":10636,"journal":{"name":"Contemporary clinical trials","volume":"146 ","pages":"Article 107695"},"PeriodicalIF":2.0000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contemporary clinical trials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1551714424002787","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Sexual and gender minority (SGM) people experience cancer disparities compared to heterosexual and cisgender (non-SGM) people and likely have barriers to cancer clinical trial enrollment. Data are sparse, however, regarding cancer clinical trial enrollment for SGM versus non-SGM people.

Methods

Using data from the 2020 Behavioral Risk Factor Surveillance Survey (BRFSS), we applied a logistic regression to assess associations between SGM status and clinical trial enrollment for 346 SGM and 9441 non-SGM people diagnosed with cancer. The model was adjusted for age at diagnosis, race/ethnicity, partnership status, education, employment, and sex assigned at birth.

Results

SGM individuals had 94 % greater odds than non-SGM individuals to report participation in a clinical trial (aOR 1.94; 95 % CI 1.02–3.68) after adjusting for other factors.

Conclusions

Data from the BRFSS suggest that SGM people with cancer have higher odds of clinical trial enrollment compared to non-SGM people with cancer. Future work is needed to prospectively track oncology treatment, including clinical trial participation, and outcomes of SGM people versus non-SGM people with cancer. Other studies will be needed to develop and implement systematic, consistent, and non-stigmatizing sexual orientation and gender identity data collection methods.

查看原文本刊更多论文

性少数群体和性别少数群体的癌症临床试验注册与异性恋、同性别的人有区别吗？

背景：与异性恋和同性（非 SGM）人群相比，性少数群体和性别少数群体（SGM）人群在癌症治疗方面存在差异，他们在癌症临床试验注册方面可能存在障碍。然而，有关 SGM 与非 SGM 人癌症临床试验注册情况的数据却很少：利用 2020 年行为风险因素监测调查（BRFSS）的数据，我们对 346 名被诊断患有癌症的 SGM 和 9441 名非 SGM 患者进行了逻辑回归，以评估 SGM 状态与临床试验注册之间的关系。该模型根据诊断时的年龄、种族/民族、伴侣状况、教育程度、就业情况和出生时的性别进行了调整：结果：在对其他因素进行调整后，SGM 患者报告参与临床试验的几率比非 SGM 患者高 94%（aOR 1.94；95 % CI 1.02-3.68）：来自 BRFSS 的数据表明，与非 SGM 癌症患者相比，SGM 癌症患者参加临床试验的几率更高。今后还需要开展工作，对 SGM 癌症患者与非 SGM 癌症患者的肿瘤治疗（包括临床试验的参与）和结果进行前瞻性跟踪。还需要开展其他研究，以制定和实施系统、一致、无污名化的性取向和性别认同数据收集方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Contemporary clinical trials 医学-药学

CiteScore

3.70

自引率

4.50%

发文量

281

审稿时长

44 days

期刊介绍： Contemporary Clinical Trials is an international peer reviewed journal that publishes manuscripts pertaining to all aspects of clinical trials, including, but not limited to, design, conduct, analysis, regulation and ethics. Manuscripts submitted should appeal to a readership drawn from disciplines including medicine, biostatistics, epidemiology, computer science, management science, behavioural science, pharmaceutical science, and bioethics. Full-length papers and short communications not exceeding 1,500 words, as well as systemic reviews of clinical trials and methodologies will be published. Perspectives/commentaries on current issues and the impact of clinical trials on the practice of medicine and health policy are also welcome.